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Abstract  
Background: Chronic pain affects more Americans than cancer, heart disease, and diabetes combined 
and has a reported economic impact of more than 600 billion dollars annually.  Despite these alarming 
statistics, the pathophysiology of chronic pain is not well understood, thus precluding the development 
of improved or novel therapeutics. In an effort to understand the underlying pathogenesis of chronic 
pain development, our group recently showed that genetic variant rs3800373 in the 3’UTR of FKBP5, 
an important regulator of the stress response, is associated with increased chronic pain severity 
following trauma exposure. In the current study, we aimed to validate this finding in an additional post-
trauma cohort, and to understand the mechanism by which this allele affects chronic pain states.  
Methods: To validate our previous genetic association results showing increased severity of chronic 
pain in individuals with the minor allele at rs3800373, we used an additional prospective cohort of 
individuals experiencing trauma. This cohort included African American (AA, n = 930) men and women 
presenting to the Emergency Department (ED) following motor vehicle collision (MVC) trauma.  RNA 
and DNA (via blood) were collected in the ED and chronic pain severity was evaluated six weeks 
following MVC using established questionnaires. Because rs3800373 is located in the 3’UTR of FKBP5 
near a microRNA-320a binding site, we used molecular and in silico assays to test whether this allele 
affects binding by miR-320a, a microRNA shown to be associated with fibromyalgia, a related pain 
disorder. 
Results:  In general linear models the influence of FKBP5 rs3800373 on chronic pain severity after 
MVC in AA depended on the level of peritraumatic distress. Individuals who reported higher levels of 
peritraumatic distress and had one or more copies of the minor allele experienced more severe pain 
six weeks following MVC than individuals with the major allele. Analysis of microRNA expression levels 
from individuals in the same study showed that in distressed individuals, lower expression levels of 
miR-320a predict increased chronic pain six weeks following MVC. Molecular studies showed that miR-
320a binds to the FKBP5 3’UTR and that in the presence of the risk allele binding is less efficient. 
Further, this difference in miRNA binding was shown via in silico analyses to be caused by allele 
dependent changes in the secondary structure conformation of the 3’UTR.   
Conclusion: These results add further evidence to the role for FKBP5 in chronic pain development 
following trauma exposure and suggest that stress dependent regulation of FKBP5 by microRNA-320a 
leads to variability in post-traumatic chronic pain development. 
  
Introduction 
Chronic pain affects more Americans than cancer, heart disease, and diabetes combined and 
has a reported economic impact of more than 600 billion dollars annually.1 One of the most common 
causes of chronic pain is exposure to traumatic/stressful events.2,3 However, little is known regarding 
the pathogenesis of post-traumatic chronic pain, precluding the development of novel therapeutics for 
secondary intervention.  
One type of traumatic event causing persistent pain development is exposure to motor vehicle 
collision (MVC). In the US, more than 10 million motor vehicle collisions (MVC) occur each year. A 
substantial proportion of individuals experiencing MVC report to Emergency Departments (EDs) for 
care, however more than 90% of the individuals do not have life threatening physical injury and are 
discharged to home after ED evaluation.4 Persistent post-MVC musculoskeletal pain (MSP) develops 
in 10-40% of individuals who experience such “minor” MVCs. Current evidence indicates that altered 
stress system signaling (e.g. glucocorticoid and catecholaminergic pathway signaling) plays an 
important role in the pathogenesis of post-MVC chronic pain.5-10  
Data supporting the role for stress system biology in post-MVC chronic MSP includes (1) a 
substantial proportion of individuals developing chronic MSP also develop neuropsychiatric diseases 
previously shown to be caused by trauma/stress, (2) peritraumatic distress at the time of injury is a 
strong predictor of chronic MSP development following MVC, (3) stress exposure in animals results in 
increased hyperalgesia compared to non-stressed animals, and (4) a number of genetic association 
studies demonstrate that polymorphisms in key glucocorticoid and catecholaminergic system genes 
predict post-MVC chronic MSP development.7,8,10,11 
Genetic association analyses are a powerful method of assessing the potential role that 
biological pathways play in post-MVC chronic MSP pathogenesis. Our group recently showed that 
polymorphisms in the glucocorticoid receptor co-chaperone, FKBP5, strongly predicts chronic MSP 
development following MVC.12 The main polymorphism that tagged the risk haplotype for chronic MSP 
following MVC, rs3800373, has previously been shown to be associated with co-morbid 
neuropsychiatric disorders such as depression and PTSD. Despite this wealth of data implicating 
rs3800373 in adverse post-traumatic sequelae, little is known regarding molecular mechanisms through 
which this polymorphism affects the pathogenesis of chronic MSP and related disorders. However, 
such studies could provide insight into the molecular pathogenesis of chronic MSP and thereby identify 
novel targets for therapeutic intervention. 
For my thesis studies, I assessed whether (1) there are allele-dependent effects of rs3800373 
on glucocorticoid resistance, an established mechanism through which FKBP5 can affect 
neuropsychiatric outcomes, (2) rs3800373, which is located in the 3’UTR of FKBP5, affects regulation 
by miR-320a, and (3) the ability of miR-320a to bind FKBP5 is affected by allelic effects on RNA 
secondary structure. This work builds upon previous work I contributed towards in the Linnstaedt lab 
showing that miR-320a predicts chronic MSP development following MVC9, and also involves a 
collaboration with Alain Laederach’s group in the Biology Department at UNC. 
 
Methods 
Study design, setting, and eligibility criteria 
A prospective longitudinal study enrolling African American individuals ≥ 18 and ≤ 65 years of age 
presenting to the ED within 24 hours of MVC was used to study chronic post-traumatic pain outcomes. 
The details of this study have been described previously.13 The study was approved by the institutional 
review boards at the data coordinating center (The University of North Carolina at Chapel Hill) and at 
all participating hospitals. Each study participant provided written informed consent before enrollment. 
Eligible and consenting participants provided blood samples in the ED and completed an ED 
interview evaluation. Interview evaluations were performed by research assistants at the time of the ED 
visit using a web-based survey with explicit definitions of variables. Injury characteristics and 
medications administered in the ED were obtained by data extraction from the ED medical record. Six 
weeks after the MVC, participants completed a follow-up interview by telephone, online, or via mail. 
Participant demographic characteristics (including age, gender, income, height, weight, and 
educational attainment) were obtained from the ED medical record and from participant self-report.  
 
DNA collection and genotyping 
Study personnel collected blood samples from each participant at the time of enrollment using PAXgene 
DNA tubes. Following DNA purification (PAXgene blood DNA kit, QIAGEN), genotyping using the 
Infinium Multi-Ethnic Global Array (Illumina) was performed.  DNA from an individual with known 
genotype (NA19819, 1000 genomes) and two repeat samples were included in each genotyping batch 
(96 samples) to ensure genotypic accuracy and reliability.  SNP rs3800373 was in Hardy-Weinberg 
equilibrium (p > 0.05) and had an excellent call rate (>99%). 
 
RNA collection and sequencing 
For RNA sample collection, research assistants collected blood samples in the ED at the time of 
enrollment using PAXgene RNA tubes. Total RNA (including miRNA) was isolated using the PAXgene 
blood miRNA kit (QIAGEN) and stored at -80˚C until use. RNA concentration and purity were measured 
using a NanoDrop 1000 (Nanodrop Technologies, Wilmington, DE). 
Small RNA sequencing: Template libraries for miRNA Next Generation Sequencing were produced 
from 1.0 ug total RNA using two similar protocols. An initial set of 69 samples (randomly chosen from 
930 participant cohort) were prepped using an adaptation of published protocols as described 
previously.14,15 A second set of 89 samples (also randomly chosen) were prepped using TruSeq Small 
RNA library prep kits according to manufacturer’s specifications (Illumina, San Diego, CA). Six samples 
were library prepped using both methods. Twelve barcoded libraries were combined per lane and 
sequenced on a HiSeq 2000 (Illumina). Raw sequence reads were processed using a custom 
bioinformatics pipeline as described previously15, and were normalized using upper quartile 
normalization. In order to normalize potential technical biases between the two methods of library 
preparation, the sequencing reads from the six samples that were prepped using both methods were 
averaged and the difference in averages between the two methods was subtracted from the values in 
the second set of samples.  
Total RNA (excluding miRNA) sequencing: Template libraries for total RNA sequencing were 
produced from 600ng total RNA using Ovation Human Blood RNA-Seq Library Systems kit (NuGen, 
San Carlos, CA) according to manufacturer’s specifications. Libraries were multiplexed in groups of six 
and sequenced on a HiSeq 2000 at the UNC High Throughput Sequencing Facility.  
 
Plasma collection and measurement of cortisol levels 
For plasma collection, research assistants collected blood samples in the ED at the time of enrollment 
using EDTA tubes. (Blood samples collected in the early morning between 5am and noon were not 
considered for analysis in order to avoid potential confounding by early morning spikes in cortisol 
levels.) To separate plasma, EDTA blood tubes were centrifuged within one hour of collection at 
1,500xg for 15 minutes and plasma was frozen at -20°C until use.   
Cortisol was measured using the MILLIPLEX MAP Steroid / Thyroid Hormone Magnetic Bead Panel 
- Endocrine Multiplex Assay (STTHMAG-21K, Millipore, Darmstadt, Germany). This assay was 
designed to measure cortisol, estradiol, and progesterone and have <10% cross-reactivity; samples 
were prepped according to the manufacturer’s specifications and assayed on a Bio-Plex 200 system 
(BioRad, Hercules, CA) using version 6.0 Bio-Plex Manager software. Data were exported to Excel 
after manual outlier removal to achieve optimal 5-Parameter Logistic fit probabilities of the standard 
curves. 
 
RT-qPCR and measurement of FKBP5 mRNA expression levels  
RT-qPCR was performed using 40 ng Total RNA from the same subset of individuals used to assess 
plasma cortisol levels. Random primers were used for reverse transcription as described (High 
Capacity Reverse Transcription Kit, Life Technologies). For qPCR, TaqMan reagents were used with 
transcript specifict primers as instructed (Life Technologies) using the TATA-box binding protein (TBP) 
gene as an endogenous control. Intron spaning primers were used for both FKBP5 (Assay ID: 
Hs01561006_m1) and TBP (Assay ID:Hs00427620_m1). 
Characterization of rs3800373 
The miRdSNP online database (http://mirdsnp.ccr.buffalo.edu/) and TargetScan16 were used to assess 
whether rs3800373 directly interferes with miRNA binding and to determine miRNAs predicted to bind 
300nt upstream or downstream of the SNP.  
 
DNA constructs 
Lentiviral constructs containing either a firefly luciferase gene (pL-SV40-GL3) or a renilla luciferase 
gene (pL-SV40-RLUC) were used for dual luciferase assays.17 All primers used for the creation of the 
following constructs are detailed in Table 2.  The 3’UTR of FKBP5 was amplified from HEK293T cells 
using primers 1-F and 1-R. The resullting 2125bp product was cloned downstream of the firefly 
luciferase gene in pL-SV40-GL3 using XhoI and EcoRI restriction enzyme sites. This newly created 
construct, pL-GL3-FKBP5-maj, was sequenced to confirm the major allele, T, at position rs3800373 in 
the FKBP5 3’UTR, and was then used as template to mutate the major allele to the minor allele, G, 
using the QuickChange II Site-Directed Mutagenesis Kit (Promega) and primers 2-F and 2-R. This new 
construct, pL-GL3-FKBP5-min, was then sequenced to confirm the presence of the minor allele and 
absence of introduced mutations.  
A shortened version of the FKBP5 3’UTR, “FKBP5-truncated”, was amplified from the full length 
3’UTR using primers 3-F and 3-R. This shortened version is 588bp and contains only the genomic 
region of the 3’UTR used to predict structural changes using RNAsnp. Mutations in three nucleotide 
positions that were predicted to disrupt complimentarity between miR-320a and the FKBP5 3’UTR seed 
binding region were engineered into FKBP5-truncated using primers 4-F and 4-R, to create a new 
construct termed “miR-320a mut”.   
The miRNA coding reigons for miR-99a, miR-122, and miR-320a  were amplified from HET293T 
cells using primers 5-F/R,6-F/R, and 7-F/R respectively. The resulting products, approximately 400bp 
in length containing the the full pre-miRNA sequence, were cloned into a pcDNA backbone using EcoRI 
and XhoI restriction sites. The pLCE-s320a sponge construct and associated controls, pLCE and pLCE 
sCXCR4 were generously donated from the Cullen Lab (Duke University).  
 
Cell culture  
HEK293T cells were grown at 37˚C, 5% CO2, in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% fetal bovine serum (FBS) and 1% gentamicin. Human neuroblastoma SK-N-AS cells were cultured 
in DMEM with 10% FBS, 0.1 mM Non-essentail Amino Acids (NEAA), and 1% gentamicin.  Other 
neuroblastoma cell lines used to test miR-320a and FKBP5 expression levels (SK-N-SH, BE-2C, SK-
N-MC, SH-SY5Y, and IMR-32) were grown as suggested by ATCC guidelines.  
 
Dual luciferase reporter assays 
Binding of miR-320a to FKBP5 3’UTR contstructs described above was assessed using FLUC and 
RLUC-based indicator vectors, pL-SV40-GL3 and pL-SV40-RLUC (also described above). HEK293T 
cells were co-transfected with 120fmol pC-320, 5fmol pL-SV40-RLUC, and 30fmol of either pL-GL3-
FKBP5-maj or pL-GL3-FKBP5-min using Fugene 6 Transfection Reagent (Promega). Seventy-two 
hours after transfection cells were collected and lysed. RLUC and FLUC levels were measured on a 
SpectraMax microplate reader (Molecular Devices) using substrates from a dual luciferase reporter 
assay kit as described (Promega); FLUC values were normalized to RLUC values and relative 
luciferase activity calculated between compared samples.  
 
Generation of neuroblastoma cells stably knocked down for miR-320a expression 
To knock down miR-320a expression in SK-N-AS cells, we stably transduced the cells with pLCE-s320, 
a miR-320 sponge construct. Such “sponge” constructs have been previously described.18 Viral 
transductants for pLCE-s320 were produced in HEK293T cells using a third generation lentiviral 
packaging system19 consisting of pMD2-VSVG, pRSV-REV, pMDLgp, and either pLCE-s330 (‘s320’), 
pLCE (GFP control), or PLCE-sCXCR4 (‘sCXCR4’, a control sponge). Each sponge construct 
contained the GFP gene. HEK293T cells were transfected using Fugene 6 Reagent (Promega). 48 
hours after transfection, viral media was collected, filtered, and concentrated using Amicon Ultra 
centrifugal columns, then added to the culture medium atop SK-N-AS cells, and integration of sponge 
sequence was monitored by GFP expression. Cells with the top 30% mean GFP fluorescence were 
sorted using FACS analysis (ARIA II) and grown in culture until sufficient numbers of cells were 
available for RNA isolation via TRIzol (Life Technologies) or for protein isolation via RIPA buffer 
(Pierce). 
 
RT-qPCR and Western blotting 
For analysis of FKBP5 mRNA expression, RNA was first treated with DNaseI (New England Biolabs) 
to remove genomic DNA. Random primers were used for reverse transcription as described (High 
Capacity Reverse Transcription Kit, Life Technologies) and SYBR reagents were used for qPCR with 
transcript specific primers as instructed (Life Technologies). Primer sequences for detecting FKBP5 
mRNA, 8-F and 8-R are shown in Table 2. Endogenous control primers were designed against GAPDH, 
9-F and 9-R; their sequences are also shown in Table 2. 
To compare FKBP5 protein levels, concentrations of protein lysate were first measured with a BCA 
Protein Assay (Pierce) and equal amounts of protein (5µg per lane) were loaded onto a 4-12% Bis-Tris 
gel (LifeTechnologies) and analyzed by Western blotting. Primary rabbit anti-FKBP5 was from Santa 
Cruz Biotechnology (sc-28983), and primary rabbit anti-β-actin was from Cell Signaling Technology 
(13E5, #4970) both at a 1:1000 dillution. Secondary anti-rabbit IgG HRP was from Cell Signaling 
Technology (#7074) at a 1:2000 dillution. Signals were developed using ECL Western Blotting 
Substrate (Pierce) and signal intensities quantified using NIH supported software, ImageJ. 
 
Analyses 
Correlation analyses were bivariate linear regression models performed using SPSS statistical software 
(IBM Corporation, Armonk, NY, U.S.A) Pearson correlation coefficients (r) and p values were derived 
from these analyses. Mann Whitney analyses were used to determine significance of differential 
microRNA binding to FKBP5 3’UTR between constructs with either major or minor alleles 
 
Selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) 
SHAPE data was obtained in vivo using the Yoruban male cell line 19098 (1000 Genomes - Coriell 
Institute for Medical Research), which is heterozygous for rs3800373 20. This cell line is lymphoblastoid 
in nature and grows in suspension. Approximately 50 million cells were spun down and resuspended 
in 1 mL of folding buffer (100mM Na-HEPES, 8.0 pH, 100mM NaCl and 10mM MgCl2) and 
supplemented with 400U murine RNase inhibitor (NEB). Cells were kept on ice and sonicated at 10% 
power for three 10 second intervals (Fisher Scientific Sonic Dismembrator Model 500). The lysate was 
incubated at 37C for 10 minutes. SHAPE treatment was carried out over five minutes with an addition 
of DMSO or three separate additions of 1-methyl-7-nitroisatoic anhydride (1M7) with a final 
concentration of 30 mM 1M7, 10% DMSO.  The DMSO alone provides a background control. RNA was 
extracted from the lysate and depleted of ribosomal RNA (ThermoFisher Trizol LS, 5PRIME PhaseLock 
Heavy, Invitrogen Purelink RNA columns, and ThermoFisher Scientific RiboMinus™ Eukaryote System 
v2 from Life Technologies). SHAPE-MaP has been previously described 21,22. Briefly, reverse 
transcription was performed with SuperScript II under special conditions (Mn2+ buffer) to convert 
adducts into mutations (ThermoFisher Scientific SuperScript II, NEB random nonamers). Primers were 
designed specific to the 3’ region of the mRNA containing rs3800373 (Supplementary Table 1), which 
was amplified by PCR (NEB Q5 HotStart). Secondary PCR was performed to add TruSeq barcodes. 
An Illumina MiSeq Sequencing Platform Sequencing was used to sequence the treated and 
background samples as a paired end, 2x300 multiplex run. 
 
  
Allele-specific sorting and SHAPE profile calculation 
Sequencing reads were aligned to the FKBP5 3′ UTR using bowtie2 (v2.2.9) 23. The aligned reads were 
then split into separate FASTQ files by the allele at the SNP position. For each allele, the SHAPE profile 
of the amplified region was derived from the allele-specific sorted sequencing reads, using the 
ShapeMapper pipeline (v1.2) 22. The SHAPE reactivity at each position corresponds to the difference 
between the mutation rate in the treatment condition and the mutation rate in the background control, 
normalizing the mutation rates by a multiplier so that the distribution of SHAPE reactivities matched 




Baseline characteristics of participants in the AA MVC study are shown in Table 1. Of 930 participants 
enrolled, 766 individuals provided DNA, were genotyped, and completed 6-week pain questionnaires. 
Total RNA was sequenced from blood samples collected from 96 participants, microRNA from 172 
participants, and cortisol from plasma of 80 participants. Due to only a subset of participants having 
plasma collected, not all participants overlapped with sequencing/cortisol data. For each subset of 
participants, most individuals were women, with an average age of 35 years and had at least high 
school education (Table 1).  
 
rs3800373 allele affects glucocorticoid resistance 
In order to determine whether the risk allele at rs3800373 affects glucocorticoid resistance, correlations 
between FKBP5 expression and (1) circulating cortisol or (2) NR3C1 mRNA levels were determined 
(Figure 1). In individuals with two copies of the major allele, there was no correlation between FKBP5 
mRNA levels and circulating cortisol levels (Figure 1A), however the correlation was significant for 
individuals with one or more copies of the minor allele (p=1.2 x 10-4) (Figure 1B). Additionally, the 
correlation between FKBP5 mRNA levels and NR3C1 mRNA expression levels was not significant for 
individuals with two copies of the major allele (Figure 1C), but was significant for those with one or more 
copies of the minor allele (p=8.3 x 10-7) (Figure 1D). 
 
The genomic locus of rs3800373 is located in the 3’UTR and affects miR-320a binding  
The location of rs3800373 in the 3’UTR of FKBP5 (Figure 2A) made it an ideal candidate as a functional 
SNP based on the immense regulatory roles established for the 3’UTR region of RNA transcripts.24,25 
The seed site for miR-320a is also broadly conserved across mammals (Figure 2B). We used luciferase 
assays to test binding to the predicted miRNA seed regions (miR-99a, 122, and 320a) (Figure 2C). The 
presence of the minor allele had a significant effect on miRNA binding only for miR-320a.  miR-320a 
binds the 3’UTR of FKBP5 containing the minor allele less efficiently (p = 0.025) than it binds the 3’UTR 
with the major allele. Figure 2D shows mutational analyses which rule out the possibility that other 
binding sites apart from the one in the SNP-related binding region of the FKBP5 3’UTR are responsible 
for miR-320a binding, indicated by the restored luciferase signal upon mutation of the miR-320a seed 
site.  
 
miR-320a regulates endogenous expression of FKBP5 in neuroblastoma cells 
The SK-N-AS neuroblastoma cell line was transduced with either a control sponge or one specific to 
miR-320a. Upon isolation of cellular RNA and protein, levels of FKBP5 were assessed. Cells which 
were treated with the s320 sponge showed higher relative expression levels of FKBP5 mRNA and 
FKBP5 protein as compared to cells transformed with the control sponge (Figure 2E).  
 
miR-320a expression correlates with FKBP5 expression in participants with the major allele 
Bivariate analyses on mRNA and miRNA sequencing data showed a correlation between FKBP5 and  
miR-320a expression levels in individuals with the major allele (r= -0.475 p=0.026). Individuals with at 
lease one copy of the minor allele did not show correlation between these RNAs (r=0.144, p=0.349). 
(Figure 2F) 
 
FKBP5 RNA adopts different secondary structures in the 3’UTR depending on the allele at 
rs3800373 
Figure 2A showed that rs3800373 is not located in a miRNA seed region. However, luciferase assays 
showed that the allele at rs3800373 affects miR-320a binding efficiency, suggesting some other 
mechanism through which the SNP alters miR-320a binding. Preliminary in silico data from RNAsnp 
predicted allele-dependent RNA secondary structures for the 3’TUR containing the minor allele versus 
the major allele (p = 0.0136, data not shown). This data suggests that rs3800373 might be a 
riboSNich.26  At the miR-320a binding site, in vivo SHAPE data showed higher SHAPE reactivity in 
mRNA transcripts containing the major allele versus transcripts with the minor allele (Figure 3A, gold 
trace). Predicted 3’UTR structures are shown in Figures 3B and 3C.  
 
Discussion 
The results of this study helped to further solidify that the SNP rs3800373 is predictive of chronic pain 
development following trauma. The process we predict to be responsible for this is through the 
development of glucocorticoid resistance in affected individuals. In her review27,  Binder summarizes 
the normal function of the HPA Axis and how FKBP5 fits into the process. Following stress exposure, 
the HPA axis is responsible for the release of glucocorticoids which have a wide array of systemic 
effects, including anti-inflammatory action. Circulating cortisol enters cells and binds to the 
glucocorticoid receptor (GR) which then serves as a transcription factor upon translocation into the 
nucleus. The result is upregulated transcription of genes important for the body's response to stress, 
including those involved in feedback loops responsible for terminating the response. One of the genes 
involved in feedback is FKBP5, a co-chaperone of the GR that when bound, reduces cortisol binding 
affinity to GR and the efficiency of the complex’s nuclear translocation. Although FKBP5 production is 
initially caused by the GR to help terminate the stress response, dysregulation of FKBP5 production 
results in overly high levels of FKBP5. Increased levels of FKBP5 lead to increases in both circulating 
cortisol and cellular GR through disruption the negative feedback that typically results from GR-cortisol 
binding. Resistance to circulating corticoids results could result in a state of chronic inflammation and 
be a potential source of chronic pain. 
Our determination of glucocorticoid resistance relies on the assertion that it is result of increased FKBP5 
levels which leads to increased levels of circulating cortisol as well as glucocorticoid receptor. The 
results in Figure 1 help to show this as a probable cause. Only in patients with the minor allele were 
the levels of these FKBP5, NR3C1, and cortisol correlated. However, if increased FKBP5 levels are 
responsible for glucocorticoid resistance, there needs to be a mechanism for stressful encounters to 
attenuate its expression under normal conditions. This mechanism could be through FKBP5 repression 
by miR-320a. Since our results showed that the minor allele reduces miR-320a binding efficiency 
through changes in the mRNA secondary structure, this would account for more uncontrolled increases 
of FKBP5 protein in individuals with the risk allele. Additionally, we would expect that for individuals 
with similar levels of miR-320a expression, those with the minor risk allele at rs3800373 would have 
increased levels of FKBP5. Our results did show that, in fact, as expected in patients with the major 
allele, there is an expected negative correlation between miR-320a expression and FKBP5 levels. This 
correlation is lost in individuals with the minor allele, suggesting that miR-320a has lost its ability to 
regulate FKBP5 expression. This result, in conjunction with, previous publications which show 
decreased levels of  miR-320a as predictive of chronic pain development9 suggest that expression of 
miR-320a may be stress induced and normally play a role in protection from glucocorticoid resistance. 
Patients with lower levels of miR-320a or an inability to respond to increasing miR-320a would in turn 
have higher FKBP5 expression and be at risk for developing chronic pain.  
Higher shape reactivity translates to increased flexibility in RNA structure. Multiple previous reports 
have demonstrated that increased RNA flexibility makes a the structure more accessible to microRNA 
binding. Therefore SHAPE data demonstrates that rs3800373 is a ribosnitch and that RNA structures 
in a representative YRI individual show increased flexibility in the miR-320a seed binding site when the 
UTR contains a T allele. The increased flexibility would suggest a more accesible seed region for miR-
320a binding, represented visually by Figures 3B and 3C. This shows that changes in secondary 
structure could be the mechanism by which rs3800373 alters miR-320 binding.  
 
As evidence increases for the importance of miRNA in regulating pain development, studies like this 
will hopefully shed insight on key ways in which miRNA regulation is disrupted and leads to a disease 
state. The fact that the miR-320a seed site is so broadly conserved across mammals suggests it could 
play an important evolutionary role. In this study, we showed that SNPs have the ability to alter mRNA 
secondary structure in such a way that miRNA binding is affected.  
There are additional ways in which chronic pain might manifest. Data from rat models has shown that 
prolonged stress exposure leads to dysregulation of normal stress pathway signaling resulting in 
nociceptor sensitization and increased hyperalgesia. Sensitization was also achieved through 
overstimulation of the glucocorticoid receptor through direct, chronic administration of cortisol.28 This 
would process would also be consistent with our assessment that adverse outcomes following MVC 
are a result of the stress associated with the trauma. The question remains then how to connect the 
two phenomena, glucocorticoid resistance and nociceptor sensitization. It is uncertain if the two 
processed are mutually exclusive or if they complement each other. It is possible that glucocorticoid 
resistance could lead to chronically elevated cortisol levels and eventual peripheral nociceptor 
sensitization and chronic pain development. However, more studies on the specifics of these processes 
would be necessary. 
One limitation to our study is the relatively small sample size for many of our sequencing analyses. 
Another is that the only tissue type we can work with in human samples is blood. Rat models of pain 
are widely used, and expanding some of the findings in this study to a rat model could help provide 
more insight on the sequence of events leading from trauma exposure to chronic pain development.  
Further studies could be done to try and confirm that changes in secondary structure are in fact what 
alters miR-320a binding. 
Conclusion 
This study provided evidence for a potential functional mechanism connecting a genetic association to 
its eventual outcome. The minor allele at rs3800373 is predictive of pain development following stress 
exposure. The change in the allele from a T to a G results in a change in secondary structure that could 
be responsible for the observed decrease in miR-320a binding efficiency to the FKBP5 3’UTR. Previous 
studies which provide evidence that miR-320a expression is stress induced, and by interfering with this 
protective measure, the minor allele at rs3800373 puts individuals at risk for glucocorticoid resistance 
and chronic pain development.  
  
Figures 
Table 1. Baseline characteristics of participants in the AA MVC study 
Characteristic Genotyping mRNA microRNA Cortisol 
Enrolled, n 930 96 172 80 
Age, years, mean (SD) 35.1 (12.7) 30.5 (10.3) 34.6 (11.8) 32.3 (10.4) 
Females, n (%) 578 (62.2) 66 (68.8) 107 (62.2) 48 (60.0) 
Education, n (%)     
   8-11 yrs 71 (7.6) 2 (2.0) 10 (5.8) 11 (13.8) 
   High School 290 (31.2) 31 (32.3) 48 (27.9) 29 (36.3) 
   Post-High School 42 (4.5) 3 (3.1) 5 (2.9) 5 (6.3) 
   Some college 338 (36.3) 42 (43.8) 77 (44.8) 25 (31.3) 
   College graduate 137 (14.7) 15 (15.6) 25 (14.5) 7 (8.8) 
   Post-graduate studies 36 (3.9) 3 (3.1) 6 (3.5) 3 (3.8) 
Overall pain severity, 0-10 NRS, mean(SD)     
   Month prior to MVC 2.2 (3.3) 1.1 (2.4) 1.6 (2.9) 1.9 (3.2) 
   ED 7.2 (2.1) 7.1 (2.2) 7.2 (2.1) 7.4 (1.8) 
   Week 6 6.0 (2.9) 4.8 (4.1) 5.5 (3.4) 6.2 (2.5) 
Peritraumatic distress in the ED, mean (SD) 22.2 (11.6) 24.3 (11.6) 23.3 (11.5) 23.5 (11.5) 
 
Table 2. Primers for DNA Constructs and SYBR qPCR analyses 
Primer 




1-F ATGATGCTCGAGGTGAACTCGGCCCCTCCTCAATGG XhoI To make 
2125 bp 
FKBP5 insert 
1-R ATGATGGAATTCGCTGACTTGGCAATCCATATGCAG EcoRI 
2-F GCTTAATTTTTAAAAACAAAATCTGTAGGGTTGACAAATAAATAGTTGCTCTTCTAC N/A Quickchange 
to create 
minor allele 
2-R GTAGAAGAGCAACTATTTATTTGTCAACCCTACAGATTTTGTTTTTAAAAATTAAGC N/A 
3-F ATCATCCTCGAGCACAGUACUUCCUCCCAGC XhoI Truncated 
588 bp 
FKBP5 
3-R ATCATCGAATTCGGGTTGCCAAATGCATTCC EcoRI 
4-F CCAUGCCGGCUUUUUUGUCUUUUUAAGAUUAUUGGC NaeI Mutate miR-
320 site to 
NaeI  
4-R CAAAAAAGCCGGCATGGATCCTAAATGAC NaeI 
5-F ATCATCGAATTCGCATCCTTAGAACTCAGC EcoRI miR-99a 
Expression 
construct 
5-R ATCATCCTCGAGGTTGAGAATTGAAGCCTGC XhoI 
6-F ATCATCGAATTCGCTCAAGATGCTTGTACC EcoRI miR-122 
Expression 
construct 
6-R ATCATCCTCGAGGAGAGGCAGGGTTCAGC XhoI 
7-F ATCATCGAATTCTCTCCGCGCCGGGC EcoRI miR-320a 
Expression 
construct 
7-R ATCATCCTCGAGCAGCTACCCCGAAGCTCC XhoI 
8-F CTCCCTAAAATTCCCTCGAATGC N/A FKBP5 
qPCR 8-R CCCTCTCCTTTCCGTTTGGTT N/A 
9-F GGAGCGAGATCCCTCCAAAAT N/A GAPDH 
qPCR 9-R GGCTGTTGTCATACTTCTCATGG N/A 
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Figure 1. Associations between circulating levels of FKBP5 mRNA and circulating cortisol levels (a, b) 
and between circulating levels of FKBP5 mRNA and circulating NR3C1 mRNA levels (c, d). These 
associations show high correlation in individuals with at least one copy of the minor allele at rs3800373 
(b, d) versus those with no copies of the minor allele (a, c). Increased levels of FKBP5 are associated 
with increased cortisol and glucocorticoid receptor mRNA (NR3C1), in individuals with the minor allele, 
suggesting development of glucocorticoid resistance. Values for Pearson correlation coefficients (r) 
and p values were derived using bivariate analyses. 
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Figure 2. miR-320a (1) binds the FKBP5 3’UTR in an allele dependent manner and (2) alters FKBP5 
expression levels in vivo. (a) rs3800373 is located in the 3’UTR of FKBP5. The three nearest predicted 
microRNA binding sites are for miR-320a, miR-122, and miR-99a. (b) The miR-320a binding site in 
FKBP5 is broadly conserved across mammals. (c) miR-99a, -122, and -320a directly bind to the FKBP5 
3’ UTR. Extent of miR-320a binding to the FKBP5 3’UTR is significantly less in the presence of the 
minor allele versus the major allele (gray bar, control; white bar with dots, major allele; black hashed 
bar, minor allele) (p = 0.025). There was no significant difference in binding between FKBP5 3’UTR 
with the major versus the minor allele for miR-99a and miR-122. (d) mutation of the miR-320a seed site 
eliminates binding of the FKBP5 3’UTR by miR-320a. (e) In neuroblastoma cells knocked down for 
miR-320a (s320) FKBP5 mRNA and protein expression are increased relative to control cells. (f) miR-
320a expression is correlated with FKBP5 expression in African American individuals with the major 

















Figure 3.  In silico data from RNAsnp show that the predicted FKBP5 3’UTR mRNA secondary 
structure is different depending on the identity of the allele at rs3800373 (a). The secondary structure 
with the major allele (left) has more loop regions than the structure with the minor allele (right), 
suggesting greater accessibility for miRNA binding. The miR-320a binding site is indicated in black 
(with a red arrow) and SNP rs3800373 is indicated by a blue arrow. In vivo SHAPE analysis of the 
FKBP5 3’ UTR in an African-derived (YRI) cell line heterozygous for rs3800373.  (b) SHAPE results 
for RNA containing the major allele (T, gold trace) vs RNA containing the minor allele (G, blue trace). 
The SNP and predicted binding locations for miR-320a and miR-122 are indicated. (c, d) predicted 
minimum free energy structures for FKBP5 3’UTR RNA with the major allele vs the minor allele based 
on SHAPE data. The predicted RNA secondary structure is different depending on the identity of the 
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